Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03138408 · ClinicalTrials.gov registry record · Phase 1
SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03138408 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 24 participants.
The verdict
NCT03138408, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a two-part study consisting of Part A (dose regimen finding) followed by Part B (dose expansion). Part A (dose regimen finding) will allow definition of the maximum tolerated dose (MTD) through dose escalation and possible dose interval modification. In Part B (dose expansion), potential therapeutic doses may be studied with SC-004 as monotherapy and SC-004 in combination with ABBV-181 in disease-specific cohorts.
Interventions
- DRUG ABBV-181
- DRUG SC-004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-06-14 |
| Est. Completion | 2019-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03138408
The ClinicalTrials.gov registry entry for NCT03138408 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABBV-181 is the first listed.
NCT03138408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03138408 about?
NCT03138408 is a clinical study titled "SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers". This is a two-part study consisting of Part A (dose regimen finding) followed by Part B (dose expansion). Part A (dose regimen finding) will allow definition of the maximum tolerated dose (MTD) through dose escalation and possible dose interval modification. In Part B (dose expansion), potential the...
What is the current status of trial NCT03138408?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-06-14. Estimated completion is 2019-05-02.
What interventions are being tested in trial NCT03138408?
The interventions under investigation include: ABBV-181 (DRUG), SC-004 (DRUG).
Who is sponsoring clinical trial NCT03138408?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.